| NĚMEC, Pavel, Henrieta GREŠLIKOVÁ, Jan SMETANA, Romana ZAORALOVÁ, Renata KUPSKÁ, Kristina BERÁNKOVÁ, Hana FILKOVÁ, Dana KRÁLOVÁ, Marta KREJČÍ, Luděk POUR, Lenka ZAHRADOVÁ, Viera SANDECKÁ, Zdeněk ADAM, Petr KUGLÍK and Roman HÁJEK. The poor prognosis associated with gain/amplification of 1q21 in relapsed multiple myeloma patients may be overcome by Velcade based regimen in contrary of thalidomide based regimen. In Haematologica/The Hematology Journal. 2008. ISSN 0390-6078. |
Other formats:
BibTeX
LaTeX
RIS
@proceedings{814135,
author = {Němec, Pavel and Grešliková, Henrieta and Smetana, Jan and Zaoralová, Romana and Kupská, Renata and Beránková, Kristina and Filková, Hana and Králová, Dana and Krejčí, Marta and Pour, Luděk and Zahradová, Lenka and Sandecká, Viera and Adam, Zdeněk and Kuglík, Petr and Hájek, Roman},
booktitle = {Haematologica/The Hematology Journal},
keywords = {multiple myeloma; Velcade; thalidomide},
language = {eng},
title = {The poor prognosis associated with gain/amplification of 1q21 in relapsed multiple myeloma patients may be overcome by Velcade based regimen in contrary of thalidomide based regimen},
year = {2008}
}
TY - CONF
ID - 814135
AU - Němec, Pavel - Grešliková, Henrieta - Smetana, Jan - Zaoralová, Romana - Kupská, Renata - Beránková, Kristina - Filková, Hana - Králová, Dana - Krejčí, Marta - Pour, Luděk - Zahradová, Lenka - Sandecká, Viera - Adam, Zdeněk - Kuglík, Petr - Hájek, Roman
PY - 2008
TI - The poor prognosis associated with gain/amplification of 1q21 in relapsed multiple myeloma patients may be overcome by Velcade based regimen in contrary of thalidomide based regimen
KW - multiple myeloma
KW - Velcade
KW - thalidomide
N2 - This study is aimed at comparison of ability to overcome the negative prognostic impact of the most common cytogenetic aberrations by treatment regimens based on Velcade or thalidomide. Both new drugs can overcome negative prognostic impact of all named chromosomal abnormalities except Amp1q21. The difference in TTP median in Amp1q21 positive and negative patients treated by thalidomide based regimen suggests that thalidomide is not able to overcome negative prognostic impact of Amp1q21 in contrary of treatment based on Velcade regimen, which probably may overcome poor prognosis of Amp1q21.
ER -
NĚMEC, Pavel, Henrieta GREŠLIKOVÁ, Jan SMETANA, Romana ZAORALOVÁ, Renata KUPSKÁ, Kristina BERÁNKOVÁ, Hana FILKOVÁ, Dana KRÁLOVÁ, Marta KREJČÍ, Luděk POUR, Lenka ZAHRADOVÁ, Viera SANDECKÁ, Zdeněk ADAM, Petr KUGLÍK and Roman HÁJEK. The poor prognosis associated with gain/amplification of 1q21 in relapsed multiple myeloma patients may be overcome by Velcade based regimen in contrary of thalidomide based regimen. In \textit{Haematologica/The Hematology Journal}. 2008. ISSN~0390-6078.
|
